Indeed, BRAF inhibitors in colorectal cancer, CDK4/6 inhibitors in breast cancer, and MEK inhibitors in melanoma all initially failed as single agents but are currently used in upfront combinations in their respective disease settings [18, 26, 34, 36]. This evidence concerns the gene CDK4 and breast carcinoma.